STOCK TITAN

[8-K] Applied DNA Sciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.

The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.

Magnite, Inc. (MGNI) ha presentato un Modulo 144 indicando una vendita pianificata di 9.289 azioni ordinarie per un valore di circa 204.358 $ ai prezzi di mercato correnti. Le azioni sono state originariamente acquisite il 15/02/2024 come azioni vincolate direttamente dall'emittente e la vendita sarà effettuata tramite Morgan Stanley Smith Barney LLC intorno al 30/06/2025. Le azioni totali in circolazione sono riportate essere 141.110.559, quindi la vendita proposta rappresenta meno dello 0,01% del flottante.

Il documento indica David Buonasera come azionista venditore, che ha già ceduto 12.395 azioni negli ultimi tre mesi per un ricavo lordo di 194.776,59 $. Sebbene gli importi in dollari siano modesti rispetto alla capitalizzazione di mercato di Magnite, vendite consecutive da parte di insider possono suscitare preoccupazioni tra alcuni investitori. Il modulo non contiene dati operativi o finanziari e non fa alcuna affermazione sui fondamentali di Magnite; si limita a divulgare l'intenzione dell'insider di vendere ai sensi della Regola 144.

Magnite, Inc. (MGNI) presentó un Formulario 144 indicando una venta planificada de 9,289 acciones comunes por un valor aproximado de $204,358 a los precios de mercado vigentes. Las acciones fueron adquiridas originalmente el 15/02/2024 como acciones restringidas directamente del emisor y la operación se realizará a través de Morgan Stanley Smith Barney LLC alrededor del 30/06/2025. El total de acciones en circulación se reporta en 141,110,559, por lo que la venta propuesta representa menos del 0,01 % del flotante.

El documento lista a David Buonasera como el accionista vendedor, quien ya ha vendido 12,395 acciones en los últimos tres meses por un ingreso bruto de $194,776.59. Aunque las cantidades en dólares son modestas en relación con la capitalización de mercado de Magnite, ventas consecutivas de insiders pueden generar preocupaciones entre algunos inversores. El formulario no contiene datos operativos o financieros ni hace afirmaciones sobre los fundamentos de Magnite; únicamente revela la intención del insider de vender bajo la Regla 144.

Magnite, Inc. (MGNI)는 9,289주의 보통주를 약 $204,358 상당으로 매도할 계획임을 나타내는 양식 144를 제출했습니다. 해당 주식은 2024년 2월 15일에 발행사로부터 직접 제한 주식으로 취득되었으며, 2025년 6월 30일경에 Morgan Stanley Smith Barney LLC를 통해 매도될 예정입니다. 총 발행 주식 수는 141,110,559주로 보고되어 있으며, 이번 매도는 유통 주식의 0.01% 미만에 해당합니다.

신고서에는 매도 주주로 David Buonasera가 명시되어 있으며, 그는 지난 3개월 동안 이미 12,395주를 매도하여 총 $194,776.59의 수익을 올렸습니다. 금액은 Magnite의 시가총액에 비해 적은 편이지만, 연속적인 내부자 매도는 일부 투자자들에게 우려를 불러일으킬 수 있습니다. 이 양식은 운영 또는 재무 성과 데이터는 포함하지 않으며, Magnite의 기본 사항에 대해 어떠한 주장도 하지 않고 단지 내부자의 매도 의도만을 Rule 144에 따라 공개합니다.

Magnite, Inc. (MGNI) a déposé un formulaire 144 indiquant une vente prévue de 9 289 actions ordinaires d'une valeur d'environ 204 358 $ aux prix du marché en vigueur. Les actions ont été initialement acquises le 15/02/2024 sous forme d'actions restreintes directement auprès de l'émetteur et la vente sera réalisée via Morgan Stanley Smith Barney LLC aux alentours du 30/06/2025. Le nombre total d'actions en circulation est rapporté à 141 110 559, ce qui signifie que la vente proposée représente moins de 0,01 % du flottant.

Le dépôt liste David Buonasera comme l'actionnaire vendeur, qui a déjà cédé 12 395 actions au cours des trois derniers mois pour un produit brut de 194 776,59 $. Bien que les montants en dollars soient modestes par rapport à la capitalisation boursière de Magnite, des ventes consécutives d'initiés peuvent susciter des inquiétudes chez certains investisseurs. Le formulaire ne contient aucune donnée opérationnelle ou financière et ne fait aucune déclaration sur les fondamentaux de Magnite ; il se limite à divulguer l'intention de l'initié de vendre conformément à la règle 144.

Magnite, Inc. (MGNI) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 9.289 Stammaktien im Wert von etwa 204.358 $ zu den aktuellen Marktpreisen anzeigt. Die Aktien wurden ursprünglich am 15.02.2024 als eingeschränkte Aktien direkt vom Emittenten erworben und sollen über Morgan Stanley Smith Barney LLC etwa am 30.06.2025 verkauft werden. Die Gesamtzahl der im Umlauf befindlichen Aktien wird mit 141.110.559 angegeben, sodass der geplante Verkauf weniger als 0,01 % des Free Floats ausmacht.

Das Formular nennt David Buonasera als verkaufenden Aktionär, der bereits in den letzten drei Monaten 12.395 Aktien veräußert hat und dabei Bruttoerlöse von 194.776,59 $ erzielte. Obwohl die Beträge im Vergleich zur Marktkapitalisierung von Magnite gering sind, können aufeinanderfolgende Insider-Verkäufe bei einigen Anlegern Besorgnis hervorrufen. Das Formular enthält keine operativen oder finanziellen Leistungsdaten und macht keine Aussagen zu den Fundamentaldaten von Magnite; es offenbart lediglich die Absicht des Insiders, gemäß Regel 144 zu verkaufen.

Positive
  • None.
Negative
  • Insider continues to sell shares, potentially signaling reduced personal confidence although amounts are immaterial.

Insights

TL;DR: Small, routine Rule 144 sale; sentiment slightly negative but immaterial financially.

The transaction involves 9,289 shares, following two earlier sales in May totaling 12,395 shares. Cumulatively, the insider will have sold about 21,684 shares—still an insignificant fraction of Magnite’s ~141 million shares outstanding. Because no additional context (e.g., option expirations, tax obligations) is provided, investors may view the pattern as mild bearish sentiment from the insider. However, the dollar value is too small to affect liquidity or ownership structure. I classify the filing as not impactful for valuation, but worth noting in governance tracking.

Magnite, Inc. (MGNI) ha presentato un Modulo 144 indicando una vendita pianificata di 9.289 azioni ordinarie per un valore di circa 204.358 $ ai prezzi di mercato correnti. Le azioni sono state originariamente acquisite il 15/02/2024 come azioni vincolate direttamente dall'emittente e la vendita sarà effettuata tramite Morgan Stanley Smith Barney LLC intorno al 30/06/2025. Le azioni totali in circolazione sono riportate essere 141.110.559, quindi la vendita proposta rappresenta meno dello 0,01% del flottante.

Il documento indica David Buonasera come azionista venditore, che ha già ceduto 12.395 azioni negli ultimi tre mesi per un ricavo lordo di 194.776,59 $. Sebbene gli importi in dollari siano modesti rispetto alla capitalizzazione di mercato di Magnite, vendite consecutive da parte di insider possono suscitare preoccupazioni tra alcuni investitori. Il modulo non contiene dati operativi o finanziari e non fa alcuna affermazione sui fondamentali di Magnite; si limita a divulgare l'intenzione dell'insider di vendere ai sensi della Regola 144.

Magnite, Inc. (MGNI) presentó un Formulario 144 indicando una venta planificada de 9,289 acciones comunes por un valor aproximado de $204,358 a los precios de mercado vigentes. Las acciones fueron adquiridas originalmente el 15/02/2024 como acciones restringidas directamente del emisor y la operación se realizará a través de Morgan Stanley Smith Barney LLC alrededor del 30/06/2025. El total de acciones en circulación se reporta en 141,110,559, por lo que la venta propuesta representa menos del 0,01 % del flotante.

El documento lista a David Buonasera como el accionista vendedor, quien ya ha vendido 12,395 acciones en los últimos tres meses por un ingreso bruto de $194,776.59. Aunque las cantidades en dólares son modestas en relación con la capitalización de mercado de Magnite, ventas consecutivas de insiders pueden generar preocupaciones entre algunos inversores. El formulario no contiene datos operativos o financieros ni hace afirmaciones sobre los fundamentos de Magnite; únicamente revela la intención del insider de vender bajo la Regla 144.

Magnite, Inc. (MGNI)는 9,289주의 보통주를 약 $204,358 상당으로 매도할 계획임을 나타내는 양식 144를 제출했습니다. 해당 주식은 2024년 2월 15일에 발행사로부터 직접 제한 주식으로 취득되었으며, 2025년 6월 30일경에 Morgan Stanley Smith Barney LLC를 통해 매도될 예정입니다. 총 발행 주식 수는 141,110,559주로 보고되어 있으며, 이번 매도는 유통 주식의 0.01% 미만에 해당합니다.

신고서에는 매도 주주로 David Buonasera가 명시되어 있으며, 그는 지난 3개월 동안 이미 12,395주를 매도하여 총 $194,776.59의 수익을 올렸습니다. 금액은 Magnite의 시가총액에 비해 적은 편이지만, 연속적인 내부자 매도는 일부 투자자들에게 우려를 불러일으킬 수 있습니다. 이 양식은 운영 또는 재무 성과 데이터는 포함하지 않으며, Magnite의 기본 사항에 대해 어떠한 주장도 하지 않고 단지 내부자의 매도 의도만을 Rule 144에 따라 공개합니다.

Magnite, Inc. (MGNI) a déposé un formulaire 144 indiquant une vente prévue de 9 289 actions ordinaires d'une valeur d'environ 204 358 $ aux prix du marché en vigueur. Les actions ont été initialement acquises le 15/02/2024 sous forme d'actions restreintes directement auprès de l'émetteur et la vente sera réalisée via Morgan Stanley Smith Barney LLC aux alentours du 30/06/2025. Le nombre total d'actions en circulation est rapporté à 141 110 559, ce qui signifie que la vente proposée représente moins de 0,01 % du flottant.

Le dépôt liste David Buonasera comme l'actionnaire vendeur, qui a déjà cédé 12 395 actions au cours des trois derniers mois pour un produit brut de 194 776,59 $. Bien que les montants en dollars soient modestes par rapport à la capitalisation boursière de Magnite, des ventes consécutives d'initiés peuvent susciter des inquiétudes chez certains investisseurs. Le formulaire ne contient aucune donnée opérationnelle ou financière et ne fait aucune déclaration sur les fondamentaux de Magnite ; il se limite à divulguer l'intention de l'initié de vendre conformément à la règle 144.

Magnite, Inc. (MGNI) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 9.289 Stammaktien im Wert von etwa 204.358 $ zu den aktuellen Marktpreisen anzeigt. Die Aktien wurden ursprünglich am 15.02.2024 als eingeschränkte Aktien direkt vom Emittenten erworben und sollen über Morgan Stanley Smith Barney LLC etwa am 30.06.2025 verkauft werden. Die Gesamtzahl der im Umlauf befindlichen Aktien wird mit 141.110.559 angegeben, sodass der geplante Verkauf weniger als 0,01 % des Free Floats ausmacht.

Das Formular nennt David Buonasera als verkaufenden Aktionär, der bereits in den letzten drei Monaten 12.395 Aktien veräußert hat und dabei Bruttoerlöse von 194.776,59 $ erzielte. Obwohl die Beträge im Vergleich zur Marktkapitalisierung von Magnite gering sind, können aufeinanderfolgende Insider-Verkäufe bei einigen Anlegern Besorgnis hervorrufen. Das Formular enthält keine operativen oder finanziellen Leistungsdaten und macht keine Aussagen zu den Fundamentaldaten von Magnite; es offenbart lediglich die Absicht des Insiders, gemäß Regel 144 zu verkaufen.

false 0000744452 0000744452 2025-06-27 2025-06-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 27, 2025

  

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

  

Delaware

(State or other jurisdiction

of incorporation)

001-36745

(Commission File Number)

59-2262718

(IRS Employer

Identification No.)

 

50 Health Sciences Drive

Stony Brook, New York 11790

(Address of principal executive offices; zip code)

  

Registrant’s telephone number, including area code:  

631-240-8800

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   APDN   The Nasdaq Stock Market

  

 

 

 

 

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

 

On June 30, 2025, Applied DNA Sciences, Inc. (the “Company”) announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic DNA manufacturing business, LineaRx. As part of actions undertaken, the Company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at Applied DNA Clinical Labs (“ADCL”), a business that provides molecular and genetic testing services, effective June 27, 2025.

 

The Company’s actions are intended to substantially reduce its operating costs and concentrate resources behind LineaRx to: (i) enhance the capabilities of LineaRx’s LineaDNA™ and LineaIVT™ platforms while scaling commercial adoption; (ii) expand its service offerings; and (iii) pursue strategic partnerships. The workforce reduction equates to a projected 23% reduction in annual payroll costs, excluding payroll expenses incurred as a result of the previously announced retirement of the Company’s former Chairman and Chief Executive Officer. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. The Company expects to incur the majority of workforce reduction-related costs by the end of the quarterly period ending September 30, 2025, excluding expenses associated with the retirement of the Company’s former Chairman and Chief Executive Officer.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective June 30, 2025, Judith Murrah, the Company’s Chief Executive Officer, President and Chairperson, voluntarily agreed to a fifteen percent (15%) temporary reduction in her annual base salary in connection with the Company’s efforts to reduce its ongoing operating expenses. Ms. Murrah’s reduced annual base salary is $340,000. The reduction is expected to end on a future date to be agreed by and between Ms. Murrah and the Compensation Committee of the Company’s Board of Directors.

 

Item 7.01 Regulation FD Disclosure.

 

On June 30, 2025, the Company issued a press release announcing the strategic restructuring and realignment of resources. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company’s belief that restructuring will position the company for future growth potential, its goal to position the company for long term-growth and value creation and the potential to achieve that goal, the future success of its Linea DNA and Linea IVT platforms and future reductions in operating expenses. All forward-looking statements reflect the Company’s beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances. Capitalized terms shall have the meanings ascribed to such terms in the Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits. 

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated June 30, 2025.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 30, 2025 APPLIED DNA SCIENCES, INC.
     
  By: /s/ Beth Jantzen
  Name: Beth Jantzen
  Title: Chief Financial Officer

 

 

 

 

FAQ

What is Magnite (MGNI) disclosing in this Form 144?

The company reports an insider’s plan to sell 9,289 common shares worth about $204k on or after 06/30/2025.

Who is selling the shares according to the filing?

David Buonasera is listed as the selling shareholder under Rule 144.

How many Magnite shares has the insider sold recently?

The insider sold 12,395 shares in May 2025 and now plans to sell an additional 9,289 shares.

What percentage of Magnite’s outstanding shares does the planned sale represent?

Less than 0.01 % of the 141,110,559 shares outstanding.

Does the filing include any financial performance data?

No, Form 144 only details the intended sale; it contains no earnings or operational metrics.
Applied Dna Scie

NASDAQ:APDN

APDN Rankings

APDN Latest News

APDN Latest SEC Filings

APDN Stock Data

2.75M
418.86k
19.47%
26.9%
5.44%
Diagnostics & Research
Services-testing Laboratories
Link
United States
STONY BROOK